GlaxoSmithKline (NYSE:GSK): Closing price $51.85
GlaxoSmithKline reports the FDA approval of its quadrivalent formulation of intramuscular Flulaval. Flulaval Quadrivalent has been cleared for the prevention of influenza caused by types A and B strains in adults and children aged 3 years and older. Flulaval Quadrivalent helps fight against two strains of influenza A and two strains of influenza B, thus giving it an advantage over the presently-available trivalent Flulaval version, which is only okayed for use in adults. The company expects the approval of Flulaval Quadrivalent to permit it to solidify its position in the market once it is made available in 2014.